HLB Therapeutics KRX:115450KOSDAQ
HLB테라퓨틱스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days1
Articles tracked0since Sep 11
In Q2 2026, HLB Therapeutics reported revenue of ₩12.6bn, down 19.9% year on year, and an operating loss of ₩4.7bn. HLB Therapeutics (HLB테라퓨틱스) appeared in 0 Korean news articles and 1 DART filing over the past seven days.
HLB Therapeutics quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩12.6bn | -19.9% | −₩4.7bn | −₩9.0bn |
| Q1 2026 | ₩13.0bn | -13.3% | −₩3.2bn | −₩4.4bn |
| Q4 2025 derived | ₩22.8bn | +38.4% | ₩4.1bn | ₩505m |
| Q3 2025 | ₩16.1bn | +14.3% | −₩5.4bn | −₩5.6bn |
| Q2 2025 | ₩15.7bn | +34.4% | −₩666m | −₩39m |
| Q1 2025 | ₩15.0bn | +18.0% | −₩1.6bn | −₩4.5bn |
| Q4 2024 derived | ₩16.5bn | +5.1% | ₩16m | ₩1.8bn |
| Q3 2024 | ₩14.1bn | -26.2% | −₩1.8bn | −₩2.6bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
HLB Therapeutics top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest HLB Therapeutics news Korean headlines
No articles yet.